GSK plc (FRA:GS71)

Market Cap	67.57B
Revenue (ttm)	37.69B
Net Income (ttm)	3.77B
Shares Out	n/a
EPS (ttm)	0.91
PE Ratio	17.93
Forward PE	8.12
Dividend	0.72 (4.33%)
Ex-Dividend Date	Feb 20, 2025

Volume	111,824
Average Volume	854,929
Open	16.88
Previous Close	16.71
Day's Range	16.26 - 16.88
52-Week Range	14.49 - 21.24
Beta	n/a
RSI	45.02
Earnings Date	Apr 30, 2025

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine product...

• Industry: Pharmaceutical Preparations
• Founded: 1715
• Employees: 68,629
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GS71

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial numbers in GBP